Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

al jishi pharmacy - ezetimibe, simvastatin - tablet - 10

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

organon pharma uk limited, united kingdom - simvastatin,ezetimibe - tablet - 20,10 mg,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

organon pharma uk limited, united kingdom - simvastatin,ezetimibe - tablet - 40,10 mg,

Namibia - English - Namibia Medicines Regulatory Council

msd (pty) ltd - ezetimibe, simvastatin - tablet - each tablet contains: ezetimibe 10 mg and simvastatin 10 mg

Namibia - English - Namibia Medicines Regulatory Council

msd (pty) ltd - ezetimibe, simvastatin - tablet - each tablet contains: ezetimibe 10 mg and simvastatin 20 mg

Namibia - English - Namibia Medicines Regulatory Council

msd (pty) ltd - ezetimibe, simvastatin - tablet - each tablet contains: ezetimibe 10 mg and simvastatin 40 mg

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe 10 mg; simvastatin 10 mg - tablets - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh.patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - tablets - simvastatin 40 mg; ezetimibe 10 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh. patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - ezetimibe; simvastatin - tablets - ezetimibe 10 mg; simvastatin 40 mg - simvastatin - simvastatin - hypercholesterolemia: inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. inegy contains ezetimibe and simvastatin. simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. homozygous familial hypercholesterolemia (hofh): inegy is indicated as adjunctive therapy to diet for use in patients with hofh. patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [ldl] apheresis).